Center for Molecular Imaging Research at MGH/HMS

MGH/HMS 分子影像研究中心

• 批准号: 7290432
• 负责人: RALPH WEISSLEDER, MD, PHD
• 金额: $ 194.2万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-08-09 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7290432
• 关键词: Achievement; Address; Algorithms; Alternative Splicing; Area; Arts; Awareness; Bacteriophages; Basic Science; Biochemical; Bioinformatics; Biological; Biological Markers; Biological Process; Biological Sciences; Biology; Biopsy Specimen; Blood; Cancer Biology; Cancer Center; Cancer Diagnostics; Cancer Hospital; Cancer Model; Cancer Patient; Cardiovascular system; Cell physiology; Cells; Characteristics; Chemical Engineering; Chemicals; Chemistry; Chromosomal translocation; Chronic Myeloid Leukemia; Clinic; Clinical; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Colorectal Cancer; Commit; Communities; Complementary DNA; Complex; Computational Biology; Computer software; Condition; Confocal Microscopy; Contrast Media; Custom; DNA Sequencing Facility; Dana-Farber Cancer Institute; Data; Data Aggregation; Databases; Decision Making; Detection; Development; Devices; Diagnosis; Diagnostic; Disease; Disease Management; Early Diagnosis; End Point; Endoscopy; Engineering; Environment; Epithelial; Event; Faculty; Figs - dietary; Foundations; Funding; Gastrointestinal Stromal Tumors; Gene Expression; General Hospitals; Generations; Genes; Genetic; Genetic Engineering; Genomics; Glioma; Goals; Grant; Half-Life; Hand; Hospital Departments; Hospitals; Human; Human Genome; Image; Image Analysis; Imaging Device; Imaging Techniques; Imatinib; Immunology; In Situ; Individual; Informatics; Information Technology; Institutes; Interdisciplinary Study; Investments; Isotope Labeling; Israel; Joints; Knowledge; Laboratories; Libraries; Life; Localized Malignant Neoplasm; Magnetic Resonance Imaging; Maintenance; Malignant Neoplasms; Malignant neoplasm of prostate; Marketing; Mass Spectrum Analysis; Massachusetts; Measurement; Medical; Medical center; Medicine; Methods; Microscopic; Mission; Modeling; Molecular; Molecular Biology; Molecular Probes; Molecular Structure; Monitor; Mouse Models of Human Cancer Consortium; Mus; NCI Center for Cancer Research; NCI-Designated Cancer Center; Nanotechnology; Neoplasms; Numbers; Optics; Organ; Outcome; Pancreas; Participant; Pathology; Pathway interactions; Patients; Performance; Pharmaceutical Preparations; Pharmacologic Substance; Phase; Phosphorylation; Phosphotransferases; Physicians; Physiological; Physiological Processes; Pilot Projects; Play; Positioning Attribute; Positron-Emission Tomography; Post-Translational Protein Processing; Postdoctoral Fellow; Preparation; Prevention; Principal Investigator; Process; Program Description; Prostate; Proteins; Proteomics; Publications; Range; Reagent; Recurrence; Regenerative Medicine; Reproducibility; Research; Research Infrastructure; Research Personnel; Resolution; Resources; Robotics; Role; Science; Scientist; Screening procedure; Seeds; Seminal; Series; Signal Transduction; Site; Source; Specimen; Staging; Standards of Weights and Measures; Stem cells; Structure; Surface; Surveys; Symptoms; System; T-Lymphocyte; TNFRSF5 gene; Techniques; Technology; Testing; Therapeutic; Therapeutic Agents; Therapeutic Intervention; Therapy Clinical Trials; Three-Dimensional Image; Time; Tissue Banks; Tissue Microarray; Today; Toxic effect; Training; Training Programs; Transcript; Transducers; Translating; Translational Research; Translations; Treatment Protocols; United States Food and Drug Administration; United States National Institutes of Health; Universities; Ursidae Family; Validation; Vision; Woman; Work; Writing; Zebrafish; anticancer research; base; bioimaging; cancer imaging; cancer research center director; cancer risk; cancer therapy; cellular imaging; chemical synthesis; cost; data acquisition; data mining; day; design; drug development; drug discovery; fight against; gene therapy; glucose metabolism; high throughput screening; human cancer mouse model; human subject; image guided therapy; imaging probe; improved; in vivo; innovation; insight; interest; killings; lectures; leukemia/lymphoma; malignant breast neoplasm; medical schools; member; millimeter; molecular imaging; mouse model; multidisciplinary; nanomaterials; nanoparticle; nanoshell; nerve stem cell; neuro-oncology; new technology; next generation; novel; novel strategies; optical imaging; optimism; postgraduate education; programs; reconstruction; response; sarcoma; scale up; size; small molecule; software development; stem; technology development; tool; treatment duration; tumor; tumor molecular fingerprint; tumorigenesis; tumorigenic

DESCRIPTION (provided by applicant): The overall goal of this P50 application is to support a highly multidisciplinary team of imaging scientists, chemists, biologists, and physicians to develop and rapidly translate new molecular imaging approaches to better diagnose, understand and treat cancer. The current team includes investigators from Massachusetts General Hospital (MGH), Dana Farber Cancer Institute, Brigham and Women's Hospital, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School (HMS), Harvard University (HU), Massachusetts Institute of Technology (MIT) and the new MIT/Harvard Broad Institute. The Program is affiliated with two NCI designated Cancer Centers: the Dana Farber Harvard Cancer Center (DFHCC) and the MIT Center for Cancer Research (CCR). Project 1 (Weissleder, Schreiber) will develop libraries of imaging agents for the rapid discovery of prostate cancer. Project 2 (Josephson, Cantley, Verdine) will develop novel approaches to image kinases (P13K, Akt) that play a key role in signal transduction and have potential for imaging therapeutic intervention upstream. Project 3 (Breakefield, Sena-Estevez) will develop novel tools to ask critical questions about neuroprecursor cells and glioma treatment. Project 4 (Pittet, von Andrian, Scadden) will apply novel imaging tools to elucidate the role of T-cells in tumor killing. A major goal of this application is to train a cadre of young investigators in the use and application of molecular imaging tools. Multidisciplinary training will involve participation in hands-on projects, seminars, didactic lecture series and funded pilot projects. A dedicated Mouse Core is in place to allow broad access to imaging in relevant cancer models in a cost-effective way, to facilitate rapid translational development and to test the in vivo distribution and efficacy of novel imaging probes. A Chemistry Core is in place to provide custom synthesized imaging probes, to scale up syntheses and develop cost-effective imaging agents. This established Center has a proven track record for innovation in molecular imaging and clinical translation and is poised to attack fundamental issues in cancer through the use of new technologies.

描述（由申请人提供）： P50应用程序的总体目标是支持由成像科学家、化学家、生物学家和医生组成的高度多学科团队开发和快速转化新的分子成像方法，以更好地诊断、理解和治疗癌症。目前的研究小组包括来自马萨诸塞州总医院（MGH）、达纳法伯癌症研究所、布里格姆妇女医院、贝丝以色列女执事医疗中心（BIDMC）、哈佛医学院（HMS）、哈佛大学（HU）、马萨诸塞州理工学院（MIT）和新的MIT/哈佛布罗德研究所的研究人员。该计划隶属于两个NCI指定的癌症中心：达纳法伯哈佛癌症中心（DFHCC）和麻省理工学院癌症研究中心（CCR）。项目1（Weissleder，Schreiber）将开发用于快速发现前列腺癌的成像剂库。项目2（Josephson，Cantley，Verdine）将开发成像激酶（P13 K，Akt）的新方法，这些激酶在信号转导中起关键作用，并有可能用于上游成像治疗干预。项目3（Breakefield，Sena-Estevez）将开发新的工具来询问有关神经前体细胞和胶质瘤治疗的关键问题。项目4（Pittet，von Andrian，Scadden）将应用新的成像工具来阐明T细胞在肿瘤杀伤中的作用。该应用程序的一个主要目标是培养一批年轻的研究人员使用和应用分子成像工具。多学科培训将包括参加实践项目、研讨会、教学讲座系列和资助的试点项目。一个专用的Mouse Core已经到位，可以以具有成本效益的方式在相关癌症模型中广泛获得成像，以促进快速翻译开发并测试新型成像探针的体内分布和功效。一个化学核心是到位，以提供定制的合成成像探针，扩大合成和开发具有成本效益的成像剂。该中心在分子成像和临床翻译方面的创新记录已得到证实，并准备通过使用新技术来解决癌症的基本问题。